Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jac/dkae121 | DOI Listing |
J Antimicrob Chemother
July 2024
III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
Molecules
February 2020
Faculty of Pharmacy, Department of Bioorganic & Pharmaceutical Chemistry, Al-Quds University, Jerusalem P.O. Box 20002, Palestine.
Background: The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected number of prodrugs have been reached the drugs market throughout history and the recent years have witnessed a significant increase in the use of prodrugs as a replacement of their parent drugs for an efficient treatment of various ailment.
Methods: A Scan conducted to find recent approved prodrugs and prodrugs in development.
Curr Opin HIV AIDS
July 2018
Clinical Research Department, Fundacion Huésped, Buenos Aires, Argentina.
Purpose Of Review: Even in the era of modern HAART, antiretroviral (ARV) failure and emergence of drug resistance is still a problem worldwide. New classes with different mechanisms of action are needed to overcome this challenge. After the integrase inhibitors were launched, more than a decade ago, no new classes were added to the ARV armamentarium.
View Article and Find Full Text PDFJ Pharm Sci
June 2013
Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Pennington, New Jersey, 08534.
BMS-663068 is a phosphonooxymethyl ester prodrug under development for the treatment of HIV/AIDS. The prodrug is designed to overcome the solubility-limited bioavailability of the active moiety, BMS-626529. BMS-663068 is not absorbed from the gastrointestinal (GI) tract and requires enzymatic conversion by alkaline phosphatase to BMS-626529 immediately before absorption.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!